Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 3/20 | 0.55 |
| ▸ | F10 | P00742 | 2/20 | 0.54 |
| ▸ | PYGL | P06737 | 9/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3447178 | 1.00 | CYP2C9 (0.55) | CYP2C9NAMPTF10PYGLKDM4E | |
| SCHEMBL3449048 | 0.93 | CYP2C9 (0.53) | CYP2C9NAMPTF10KDM4EPKM | |
| SCHEMBL3449051 | 0.93 | CYP2C9 (0.53) | CYP2C9NAMPTF10KDM4EPKM | |
| SCHEMBL22533699 | 0.88 | CYP2C9 (0.58) | CYP2C9NAMPTKDM4EPKM | |
| SCHEMBL3336715 | 0.81 | F10 (0.63) | F10 | |
| SCHEMBL2940528 | 0.81 | F10 (0.63) | F10 | |
| SCHEMBL3336718 | 0.81 | F10 (0.63) | F10 | |
| SCHEMBL3450135 | 0.81 | NAMPT (0.51) | NAMPTKDM4EPKMHRH4MEN1 | |
| SCHEMBL3450134 | 0.81 | NAMPT (0.51) | NAMPTKDM4EPKMHRH4MEN1 | |
| SCHEMBL4591847 | 0.81 | NAMPT (0.51) | NAMPTKDM4EPKMHRH4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820699-B2 | Cyclic amines | HOFFMANN-LA ROCHE INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820699-B2 | Cyclic amines | HOFFMANN-LA ROCHE INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820699-B2 | Cyclic amines | HOFFMANN-LA ROCHE INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1877404-A2 | NOVEL CYCLIC AMINES | F. Hoffmann-Roche AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114401-A2 | NOVEL CYCLIC AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006114401-A2 | NOVEL CYCLIC AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | WO | disclosed |
| US-20060247238-A1 | Cyclic amines | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247238-A1 | Cyclic amines | F12, F11, F2 | CYP2C9 430/4885NAMPT 2110/4885F10 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.